This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
March 13, 2013 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced that its To Go Brands
® operating unit has expanded its VitaRocks
® kids vitamins product line and that retail distribution of the newly-designed products is being been broadened into select Target stores.
The VitaRocks products are inspired by a popping pellet candy that is popular with kids and represents a next-generation, easy-use delivery platform for multivitamins and nutrients, dietary supplements, and potentially over-the-counter (OTC) medicines for children as well as adults. The Kids VitaRocks product line is fun, and uses tasty antioxidant and mineral-rich formulas to provide vitamins A, B, C, D and E, as well as calcium, iodine, magnesium, zinc and selenium. Each packet provides 50% of Daily Value, so that children four and above may enjoy this nutritious treat twice a day. VitaRocks products include cherryBLAST, grapeGUSHER, the new blueRAZZ, as well as orangeBURST, providing 250 mg of Vitamin C. To
Go Brands' adult VitaRocks C delivers a powerful dose of 1000 mg of Vitamin C in every packet.
"Special formulations allow VitaRocks to melt cleanly in the mouth and deliver vitamins and nutrients while being fun and great tasting. Unlike many other products in this class, VitaRocks require no mixing with water and can be directly consumed. While the initial product line was designed for children, with the success of new adult multivitamin chews and gummies, consumers of all ages are increasingly seeking easy-to-use and great tasting nutritional products, and we believe that our VitaRocks platform aligns with this important and rapidly emerging trend. Because of our unique manufacturing process, we now have the flexibility to expand the product line into formulas that could include enzymes, electrolytes, amino acids, vitamins and minerals, as well as nutrients, and into other applications including OTC drugs," stated
Hanna Wagari, Cardium's Vice President of Sales and Marketing.
Current VitaRocks products are available through retailers, including Whole Foods, Sprouts and Vitamin Shoppe. The new product line will be available at the beginning of
April 2013 in select Target stores, as well as directly from the To Go Brands web-based store at www.
About To Go Brands
Since 2007, To Go Brands has been making healthy, great tasting and anti-oxidant-rich phytonutrients and nutraceutical supplements in an array of easy use formats, including drink mixes, chews, powders and capsules, to empower busy lifestyles in today's fast-paced, tech-driven world. The Go Active! product line includes High Octane
®, Green Tea Energy Fusion™, Acai Natural Energy Boost™, and Neo-Energy
®. The Go Healthy! product line includes Greens to Go
®, Extreme Berries to Go
®, Healthy Belly
®, and Neo-Chill™.
Go Trim! products include Smoothie Complete
®, Trim Energy Green Coffee Bean™, Trim Energy
®, and Neo-Carb Bloc
®. To Go Brands products are sold through mass, food and drug channels at retailers including Whole Foods, Sprouts, Kroger, GNC, RiteAid, Jewel-Osco, Ralph's Supermarkets, Vitamin World, Meijer,
Fred Meyer, King Soopers, and the Vitamin Shoppe
® as well as directly from the company's web-based store. To learn more about To Go Brands, visit
Cardium is an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization, partnering or other economic monetizations. Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company's newly-acquired To Go Brands
® nutraceutical business. The Company's lead commercial product, Excellagen
® topical gel for wound care management, has received FDA clearance for marketing and sale in the United States. Cardium's lead clinical development product candidate Generx
® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. To
Go Brands® develops, markets and sells dietary supplements through established regional and national retailers. In addition, consistent with its business model, Cardium continues to actively evaluate new technologies and business opportunities. For more information, visit
Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from expectations. For example, there can be no assurance that To Go Brands products or Cardium's other products can be successfully commercialized; that the retail distribution of VitaRocks or other products will be successfully expanded; that new products will be developed and launched in a timely and effective manner; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive, or will not be blocked by third party intellectual property rights or other means; that our products will substantially enhance our revenues or perceived value; that the company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that third parties on whom we depend will perform as anticipated; that we can raise sufficient capital from partnering, monetization or other fundraising transactions to maintain our stock exchange listing or adequately fund ongoing operations; or that we will not be adversely affected by these or other risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.